inspiremd, inc. is a company based out of 800 boylston street suite 16041, boston, massachusetts, united states.

Company profile
Ticker
NSPR
Exchange
Website
CEO
Marvin Slosman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Saguaro Resources, Inc.
SEC CIK
Corporate docs
IRS number
262123838
NSPR stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
13 Sep 23
8-K
InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23
31 Aug 23
8-K
InspireMD Reports Second Quarter 2023 Financial Results and Provides
8 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
8-K
Departure of Directors or Certain Officers
21 Jul 23
PRE 14A
Preliminary proxy
18 Jul 23
8-K
InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial
26 Jun 23
424B3
Prospectus supplement
2 Jun 23
Transcripts
NSPR
Earnings call transcript
2023 Q2
8 Aug 23
NSPR
Earnings call transcript
2023 Q1
16 May 23
NSPR
Earnings call transcript
2022 Q4
30 Mar 23
NSPR
Earnings call transcript
2022 Q3
8 Nov 22
NSPR
Earnings call transcript
2022 Q2
9 Aug 22
NSPR
Earnings call transcript
2022 Q1
10 May 22
NSPR
Earnings call transcript
2021 Q4
8 Mar 22
NSPR
Earnings call transcript
2021 Q3
9 Nov 21
NSPR
Earnings call transcript
2021 Q2
10 Aug 21
NSPR
Earnings call transcript
2021 Q1
11 May 21
Latest ownership filings
4
Shane Thomas Gleason
30 Aug 23
4
GARY S ROUBIN
5 Jul 23
4
Thomas J Kester
5 Jul 23
4
MICHAEL BERMAN
5 Jul 23
4
Kathryn Arnold
5 Jul 23
SC 13D
Shore Craig
16 Jun 23
SC 13G
Rosalind Advisors, Inc.
8 Jun 23
SC 13G
Soleus Private Equity Fund III, L.P.
24 May 23
SC 13G
Marshall Wace North America L.P.
22 May 23
4
Marvin Slosman
19 May 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.55 mm | 11.55 mm | 11.55 mm | 11.55 mm | 11.55 mm | 11.55 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.77 mm | 1.60 mm | 1.11 mm | 1.37 mm |
Cash used (since last report) | n/a | n/a | 5.00 mm | 4.52 mm | 3.13 mm | 3.87 mm |
Cash remaining | n/a | n/a | 6.55 mm | 7.02 mm | 8.42 mm | 7.68 mm |
Runway (months of cash) | n/a | n/a | 3.7 | 4.4 | 7.6 | 5.6 |
Institutional ownership, Q2 2023
73.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 26 |
Opened positions | 14 |
Closed positions | 2 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 20.19 bn |
Total shares | 15.60 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Soleus Private Equity Fund III | 2.20 mm | $3.70 mm |
Orbimed Advisors | 1.86 mm | $4.67 bn |
Marshall Wace | 1.86 mm | $4.67 bn |
Marshall Wace North America | 1.86 mm | $2.70 mm |
Nantahala Capital Management | 1.86 mm | $4.67 bn |
Rosalind Advisors | 1.86 mm | $3.44 mm |
Intracoastal Capital | 1.45 mm | $494.00 k |
Soleus Capital Management | 1.38 mm | $3.46 bn |
Velan Capital Investment Management | 904.03 k | $2.27 bn |
Lind Global Macro Fund | 177.33 k | $527.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
28 Aug 23 | Shane Thomas Gleason | Common Stock | Grant | Acquire A | No | No | 0 | 19,290 | 0.00 | 275,740 |
28 Aug 23 | Shane Thomas Gleason | Options to purchase common stock Common Stock | Grant | Acquire A | No | No | 3.37 | 6,430 | 21.67 k | 91,910 |
17 May 23 | Slosman Marvin | RSU | Grant | Acquire A | No | No | 0 | 1,045,150 | 0.00 | 1,288,620 |
17 May 23 | Slosman Marvin | Options to purchase common stock Common Stock | Grant | Acquire A | No | No | 1.76 | 348,380 | 613.15 k | 467,406 |
17 May 23 | Craig Shore | Common Stock | Grant | Acquire A | No | No | 0 | 522,580 | 0.00 | 641,219 |
17 May 23 | Craig Shore | Options to purchase common stock Common Stock | Grant | Acquire A | No | No | 1.76 | 174,190 | 306.57 k | 220,270 |
17 May 23 | Paul Stuka | Common Stock | Grant | Acquire A | No | No | 0 | 225,680 | 0.00 | 268,000 |
17 May 23 | Paul Stuka | Options to purchase common stock Common Stock | Grant | Acquire A | No | No | 1.76 | 75,220 | 132.39 k | 89,228 |
17 May 23 | Andrea Tommasoli | Common Stock | Grant | Acquire A | No | No | 0 | 179,080 | 0.00 | 256,453 |
17 May 23 | Andrea Tommasoli | Options to purchase common stock Common Stock | Grant | Acquire A | No | No | 1.76 | 59,690 | 105.05 k | 85,481 |
News
InspireMD Announces Abstract Of 30-Day Results From The C-Guardians U.S. Investigational Device Exemption Clinical Trial Accepted for Presentation at VIVA23
31 Aug 23
12 Health Care Stocks Moving In Wednesday's After-Market Session
23 Aug 23
InspireMD Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $1.65M Beat $1.55M Estimate
8 Aug 23
Earnings Scheduled For August 8, 2023
8 Aug 23
12 Health Care Stocks Moving In Friday's After-Market Session
21 Jul 23